Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Inside The Lupus Pipeline: Reasons For Optimism

Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.

Clinical Trials Immune Disorders Market Intelligence

CRISPR Therapeutics President Sam Kulkarni On Business Development

CRISPR Therapeutics hopes its partnered lead program in sickle cell disease and beta-thalassemia therapies will generate a product launch within the next four to five years.

Business Strategies Commercial Companies

Pfizer Upbeat After Bagging Besponsa Approval in US

It is the first CD22-directed antibody-drug conjugate indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, though sales potential is modest.

Approvals Cancer Companies
Advertisement

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies Market Intelligence


 Recent Tweets from Scrip


Commercial Explore this Topic

Minimum Stada Takeover Level Reached Just In Time By Bain And Cinven

A last-minute surge in shareholder acceptances has pushed Bain and Cinven's €5.4bn takeover offer for Stada Arzneimittel over the finish line just in time.

M & A Generic Drugs Companies

Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.

Financing Business Strategies Regenerative Medicine

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.

Deals Business Strategies

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Business Strategies Regulation

Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way

FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.

Cardiovascular Market Intelligence

Time Is Of The Essence As Teva Considers European Assets Bids

Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.

M & A Cancer

Agenovir: Using Gene Editing To Kill Viral DNA

Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.

StartUps and SMEs Business Strategies

The Eyes Have It For Shire With Lifitegrast Filing In Europe

The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis

Ophthalmic Approvals

Policy & Regulation Explore this Topic

Stem Cell Therapy Gets Boost With NICE Nod For Chiesi's Holoclar

Single treatment for one eye costs £80,000 but Chiesi is offering a discount for Europe's first approved stem cell medicinal product.

Regenerative Medicine Reimbursement Ophthalmic

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

Approvals Research & Development

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Business Strategies Regulation

Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way

FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.

Cardiovascular Market Intelligence

Research & Development Explore this Topic

J&J’s India TB R&D Alliance – Can It Pull Off Something Special?

Johnson & Johnson’s tuberculosis R&D partnership with the Institute of Microbial Technology in India aims to develop shorter, simpler and safer TB regimens. The alliance has, at its forefront, an expert from the team that developed Sirturo (bedaquiline).

Research & Development Infectious Diseases India

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

Approvals Research & Development

Mateon's CA4P Disappoints At Second Interim Analysis, More Data Awaited

A third interim analysis, in September, may clarify whether Mateon’s vascular disrupting agent is likely to be therapeutically useful as a new class of agents for ovarian cancer.

Clinical Trials Companies

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.

Research & Development South Korea
UsernamePublicRestriction

Register

Advertisement